Gilead Sciences, Inc. $GILD Shares Sold by Foundation Resource Management Inc.

Foundation Resource Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 98,374 shares of the biopharmaceutical company’s stock after selling 3,773 shares during the period. Gilead Sciences accounts for 1.2% of Foundation Resource Management Inc.’s holdings, making the stock its 26th biggest position. Foundation Resource Management Inc.’s holdings in Gilead Sciences were worth $14,663,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Bank of Nova Scotia acquired a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $100,056,000. Groupe la Francaise grew its stake in shares of Gilead Sciences by 30.9% in the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after buying an additional 11,712 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $55,754,000. Baird Financial Group Inc. increased its holdings in Gilead Sciences by 3.6% in the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after buying an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new position in Gilead Sciences in the second quarter worth approximately $6,251,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director owned 10,066 shares in the company, valued at $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the completion of the transaction, the chief executive officer directly owned 566,683 shares in the company, valued at approximately $83,812,415.70. This represents a 2.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 111,000 shares of company stock worth $15,877,860. 0.30% of the stock is currently owned by company insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported positive Phase 2 SWIFT results for emvistegrast, an oral treatment for active ulcerative colitis. The drug met the trial’s primary goal, strengthening Gilead’s inflammatory bowel disease pipeline and potentially creating a future growth opportunity beyond its core HIV franchise. Gilead’s pill succeeds in mid-stage bowel disease trial
• Positive Sentiment: Gilead received a Zacks Rank upgrade to No. 2, or “Buy,” reflecting improved expectations for earnings and the possibility of continued near-term investor interest. Gilead rating upgrade to Buy
• Positive Sentiment: The company is scheduled to present 28 sets of HIV, HIV-prevention and antiviral research at IDWeek 2026, offering potential visibility into future products and additional clinical catalysts. Gilead to present new data at IDWeek 2026
• Neutral Sentiment: Reports noted that 43 exchange-traded funds added Gilead shares, indicating institutional demand, although ETF purchases are unlikely to materially change the company’s fundamentals. 43 ETFs add Gilead Sciences
• Neutral Sentiment: Recent acquisitions, including Arcellx and Tubulis, expand Gilead’s pipeline but raise questions about integration, costs and their effect on the steady profits and dividend investors expect from its HIV business. What has changed about owning Gilead stock
• Negative Sentiment: Two company insiders, Andrew Dickinson and Johanna Mercier, each reportedly sold 3,000 shares. These transactions may create a modest negative sentiment signal, although they are small relative to Gilead’s market value. Insider Andrew Dickinson sells shares Insider Johanna Mercier sells shares

Gilead Sciences Stock Down 2.0%

Shares of NASDAQ:GILD traded down $3.12 on Monday, reaching $153.07. The company had a trading volume of 6,834,634 shares, compared to its average volume of 6,823,617. Gilead Sciences, Inc. has a twelve month low of $114.02 and a twelve month high of $160.51. The stock has a 50-day moving average price of $147.19 and a 200 day moving average price of $137.29. The stock has a market capitalization of $189.80 billion, a P/E ratio of -57.33 and a beta of 0.31. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.01 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post -0.47 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.1%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences’s payout ratio is -122.85%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GILD. Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $123.00 to $126.00 and gave the company a “sector perform” rating in a research report on Thursday, October 8th. HSBC boosted their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Needham & Company LLC reissued a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Finally, Morgan Stanley cut their price target on shares of Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating on the stock in a report on Wednesday, October 7th. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $159.33.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.